Tryton Medical - Tryton 1

TRYTON l


		In October 2007 Prof. Patrick Serruys of Erasmus Medical Center, the Netherlands presented six-month clinical and angiographic results from the Tryton 1 (First-In-Man Study) of the Tryton Side Branch Stent System™. At six-month follow up, none of the patients suffered from side-branch restenosis. Core laboratory quantitative analysis reported a late loss of 0.27 ± 0.42 mm in the side branch and 0.12 ± 0.47 mm in the main vessel. “The core angiographic data demonstrates that the hybrid approach – a bare metal Tryton Side Branch Stent used in conjunction with a standard drug eluting stent – provides the same type of restenosis reduction we have seen when drug eluting stents are used to treat standard lesions,” said Prof. Serruys. “This is the first time I have seen such promising results in the treatment of bifurcation disease.”



		Additional European clinical trials of the Tryton Side Branch System include Tryton II, an intravascular ultrasound (IVUS) series study enrolling thirty patients; Tryton III, an OCT series study enrolling 15 patients; and Tryton IV, a feasibility study of the device in the left main coronary artery. The company also plans a large multi-center prospective study evaluating the Tryton Side Branch System in real-life practice.

		The Tryton Side Branch Stent System™ is currently not available for clinical trials or commercialization in the USA.